GATC Health Featured in Pharma Tech Outlook, “Transforming Drug Development with AI that Mimics Human Physiology”

“In less than a year, GATC Health has discovered and is developing three new drug candidates to treat fentanyl addiction, cocaine addiction and PTSD.”IRVINE, Calif., April 27, 2023 — GATC Health Corp, a technology company advancing drug discovery and disease prediction using artificial intelligence (AI), was recently featured in Pharma Tech Outlook, an industry publication that highlights breakthroughs in pharmaceutical infrastructure, tools and services for industry decision makers. The article, “Transforming Drug Development with AI that Mimics Human Physiology,” illustrates the company’s unique ability to create new drugs in record time that are safer, and more efficacious at a significant savings to traditional methods. GATC’s platform also substantially de-risks assets, delivering drug candidates that have been pre-screened to 88% accuracy to have a beneficial effect in humans.

From the article:

GATC’s MAT platform surpasses other drug discovery AI technology by simulating human biochemistry’s billions of interactions for accurate and rapid novel target identification, drug discovery, drug development and repurposing of failed drugs.

“Because of the high-stakes binary success/fail [pharma] business model, using AI to predict success and failure early in the process is a necessity,” says Tyrone Lam, GATC’s COO. “GATC’s ability to predict which compounds are most likely to succeed, combined with our capacity to produce ten to twelve new drug candidates each year, could produce billions of dollars in potential value.”

Read the whole article here: https://www.pharmatechoutlook.com/gatc-health.

About GATC Health

GATC Health Corp is a technology company revolutionizing disease prediction and drug discovery and development through its transformative AI platform and approach, which de-risks drug pipelines and accelerates new therapies to treat disease with accuracy, efficiency and speed never before achieved in medical science. The company’s validated and proprietary Multiomics Advanced Technology™ (MAT) platform simulates human biochemistry’s billions of interactions for accurate and rapid disease prediction, novel target identification, and drug discovery and development. GATC envisions the future of medicine now, where health is protected, disease is reversed and every person’s unique biology is treated with precision.